



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)

Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 30th May 2022

To,
The Company Secretary,
Corporate Compliance Department,
The National Stock Exchange of India Limited,
Bandra Kurla Complex, Mumbai

To,
The Company Secretary,
Corporate Compliance Department,
BSE Limited,
Dalal Street, P.J. Tower, Mumbai

Sub: Outcome of Board Meeting held on Monday 30th May 2022 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ref: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Script Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

With reference to the above captioned subject, we would like to inform you that Board of Directors of the Company in their meeting (Serial No. 01/2022-23) held on today i.e., Monday, 30th day of May, 2022, has inter alia, transacted following matters along with other routine businesses:

1. Approved Audited Financial Results of the Company for the quarter as well as year ended 31st March, 2022 along with Audit Report thereon, Statement of assets and liabilities, Cash Flow Statement and declaration from the Managing Director of the Company pursuant to second proviso of Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015. *Copy of results being submitted separately.*
2. Re-appointment of Mr. L.N. Joshi and Company, Practicing Company Secretaries as Secretarial Auditors of the Company for the Financial Year 2022-23.

The Meeting of the Board of Directors commenced at 7.00 pm and concluded at 8.05 pm.

This is for your information and record.

Thanking you.

Yours Faithfully,

FOR BIOFIL CHEMICALS & PHARMACEUTICALS LIMITED


Shikha Khilwani
Company Secretary
ACS: 43203





BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 30th May 2022

| | |
|--|---|
| To, The Company Secretary, Corporate Compliance Department, The National Stock Exchange of India Limited, Bandra Kurla Complex, Mumbai | To, The Company Secretary, Corporate Compliance Department, BSE Limited, Dalal Street, P.J. Tower, Mumbai |
|--|---|

Sub: Submission of Audited Financial Results for the Quarter as well as year ended 31st March, 2022 in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are here enclosing the Audited Financial Results for the quarter as well as year ended 31st March, 2022 duly approved by the Board of Directors at its meeting held today i.e. Monday, 30th May, 2022 together with Audit Report thereon, Statement of assets and liabilities, Cash Flow Statement & declaration by the Managing Director of Company pursuant to second proviso of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 .

Further above said results shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The results shall also be uploaded on the Company's website i.e. www.biofilgroup.net and on the website of the Stock Exchanges i.e., at www.bseindia.com & www.nseindia.com and extracts of the aforesaid results shall also be published in Hindi (Vernacular) and widely circulated English Newspaper.

You are requested to take on record the above said financial results for your reference and record.

Thanking you.

Yours Faithfully,

For Biofil Chemicals & Pharmaceuticals Limited


Shikha Khilwani
Company Secretary
ACS: 43203

Enclosure: Audited Financial Results along with auditor's report for the quarter as well as year ended 31st March, 2022



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date:-30.05.2022

To,

The Manager,
Listing Department
BSE Limited

Phiroze Jeejeebhoy Towers Dalal Street,
Mumbai

The Manager,
Listing Department

The National Stock Exchange of India Limited
Bandra Kurla Complex, Mumbai

Sub: Submission of declaration regarding unmodified opinion of the Auditors on Annual Audited Financial Results of the Company for the year ended 31st March, 2022 as per second proviso to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015

REF: - BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED (BSE Script Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 I, the undersigned do hereby declare that in the Audit Report accompanying the audit report accompanying the Annual Audited Financial Statements of **BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED** for the financial year ended on 31st March, 2022, the Statutory Auditor M/s Maheshwari & Gupta and Company, Chartered accountants did not express any modified opinion/audit qualification or other reservation and accordingly, the Statement on Impact of Audit Qualifications is not required to be given.

You are requested to please consider and take on record the same.

Thanking You,

Yours Faithfully,

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

Ramesh Shah

Chairman and Managing Director

(DIN: 00028819)



BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN NO. L24233MP1985PLC002709

Regd Off: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.) 452015


Email Id: bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net

(Amount in Lakhs except EPS)

Statement of Audited Financial Results for the Quarter and Year ended 31st March 2022

| Sr No. | Particulars | Quarter Ended | | | Year Ended | |
|--------|---|----------------|-------------------|----------------|----------------|----------------|
| | | March 31, 2022 | December 31, 2021 | March 31, 2021 | March 31, 2022 | March 31, 2021 |
| | | Audited | Un-Audited | Audited | Audited | Audited |
| I | Revenue from Operation | 164.55 | 163.02 | 1423.87 | 2238.23 | 3575.04 |
| II | Other Income | 3.01 | 6.85 | (0.43) | 15.03 | 79.99 |
| III | Total Income | 167.56 | 169.87 | 1423.44 | 2253.26 | 3655.04 |
| IV | Expenses | | | | | |
| | (a) Cost of materials consumed | 40.30 | 39.95 | 130.33 | 226.76 | 685.12 |
| | (b) Purchases of stock-in-trade | 5.27 | 56.34 | 1546.90 | 1360.27 | 2834.43 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 51.07 | (16.84) | (335.19) | 359.01 | (276.86) |
| | (d) Employee benefits expense | 23.59 | 17.72 | 11.50 | 78.67 | 75.16 |
| | (e) Finance Cost | 1.02 | 1.09 | (8.51) | 4.06 | 6.81 |
| | (f) Depreciation and Amortisation Expense | 11.86 | 10.30 | 18.93 | 42.75 | 41.19 |
| | (g) Other expenses | | | | | |
| | 1. Manufacturing Expenses | 14.55 | 10.60 | 16.65 | 41.48 | 55.57 |
| | 2. Administrative Expenses | 14.92 | 5.42 | 16.02 | 34.85 | 32.46 |
| | 3. Selling and Distribution Expenses | 0.66 | 1.25 | 0.53 | 3.92 | 9.26 |
| | Total expenses | 163.25 | 125.83 | 1397.17 | 2151.77 | 3463.14 |
| V | Profit/ (Loss) before exceptional items and tax | 4.31 | 44.04 | 26.27 | 101.49 | 191.90 |
| VI | Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| VII | Profit/ (Loss) before tax | 4.31 | 44.04 | 26.27 | 101.49 | 191.90 |
| VIII | Tax expense: | | | | | |
| | (1) Current tax | 2.61 | 10.00 | 32.75 | 27.10 | 32.75 |
| | (2) Deferred tax | 4.55 | 0.00 | 35.01 | 4.55 | 35.01 |
| | Total Tax expenses | 7.16 | 10.00 | 67.76 | 31.65 | 67.76 |
| IX | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| X | Profit/(Loss) for the period from continuing operation | (2.85) | 34.04 | (41.49) | 69.84 | 124.14 |
| XI | Profit/(Loss) for the period for dis-continued operation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XII | Tax expenses of discontinued operation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XIII | Profit/(Loss) for the period for dis-continued operation after tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XIV | Profit/ (Loss) for the period | (2.85) | 34.04 | (41.49) | 69.84 | 124.14 |
| XV | Other Comprehensive Income | | | | | |
| | A) (I) Items that will not be reclassified to Profit or Loss | 1.35 | 0.00 | 0.63 | 1.35 | 0.63 |
| | (II) Income Tax relating to items that will not be reclassified to Profit or Loss | (0.34) | 0.00 | (0.18) | (0.34) | (0.18) |
| | B) (i) Items that will be reclassified to Profit or Loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | (II) Income Tax relating to items that will be reclassified to Profit or Loss | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XVI | Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period) | (1.84) | 34.04 | (41.03) | 70.86 | 124.59 |
| XVII | Paid-Up equity share capital (face value of Rs 10/- each) | 1627.38 | 1627.38 | 1627.38 | 1627.38 | 1627.38 |
| XVIII | Reserves (Excluding Revaluation Reserve) | | | | (319.82) | (390.50) |
| XIX | Earnings per equity shares (for continuing operation): | | | | | |
| | (1) Basic (Rs) | (0.01) | 0.21 | (0.25) | 0.44 | 0.77 |
| | (2) Diluted (Rs) | (0.01) | 0.21 | (0.25) | 0.44 | 0.77 |

Raw



| XX | Earnings Per Equity Share (for discontinued operation) | | | | | |
|-----|---|--------|------|--------|------|------|
| | (1) Basic (Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | (2) Diluted (Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| XXI | Earnings Per Equity Share (for continuing & discontinued operation) | | | | | |
| | (1) Basic (Rs) | (0.01) | 0.21 | (0.25) | 0.44 | 0.77 |
| | (2) Diluted (Rs) | (0.01) | 0.21 | (0.25) | 0.44 | 0.77 |

- 1 The above Audited results for the Quarter and financial year ended March 31, 2022 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 30-05-2022. The above results have been audited by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3 The figures for the quarter ended 31st March 2022 and 31st March 2021 are the balancing figures between the audited figures in respect of the full financial year and the years to date figures up to the third quarter.
- 4 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
a. Pharma Product
b. Chemicals Division
- 5 Statutory Auditors of the Company has carried out audit of the books of accounts for the financial year 2021-2022 and issued us an Audit Report with unmodified opinion on Audited Financial Year for the quarter/year ended on 31st March, 2022, therefore the Company is not required to give statement of impact of Audit Qualification for Audit Report with modified opinion
- 6 The aforesaid audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors
- 7 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 8 The Statement of Assets & Liabilities as on at March 31, 2022 is annexed with the results along with the Statement of Cash Flow.
- 9 Effective 1 April, 2019, the Company has adopted Ind AS 116- 'Leases' using modified retrospective approach. This has resulted in recognition of right of use assets equal to lease liabilities as on 1 April, 2019. The adoption of the standard did not have any material impact on the audited standalone financial results.

Date : 30/05/2022
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED


RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)



Segmentwise Revenue, Results and Capital Employed for year ended 31st March 2022

| S.No. | Particulars | (Amount in Lakhs) | | | | |
|-------|--|--------------------|----------------------|-------------------|-------------------|-------------------|
| | | Quarter Ended | | | Year Ended | |
| | | March 31, 2022 | December 31, 2021 | March 31, 2021 | March 31, 2022 | March 31, 2021 |
| | | Audited | Un-Audited | Audited | Audited | Audited |
| 1 | Segment Revenue | | | | | |
| | Pharma Division | 20.42 | 106.60 | 1,213.33 | 1,900.52 | 2,700.01 |
| | Chemical Division | 144.13 | 56.42 | 210.54 | 337.71 | 875.03 |
| | Other | 3.01 | 6.85 | (0.43) | 15.03 | 79.99 |
| | Net sales/Income From Operations | 167.56 | 169.87 | 1,423.44 | 2,253.26 | 3,655.04 |
| 2 | Segment Results (Profit)(+)/ Loss (-) before tax and interest | | | | | |
| | Pharma Division | (11.06) | 40.56 | 14.09 | 98.70 | 116.80 |
| | Chemical Division | 15.75 | 4.04 | 10.89 | 4.63 | 79.41 |
| | Other | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | Total Segment Profit Before Tax | 4.69 | 44.61 | 24.98 | 103.33 | 196.21 |
| | Interest Income | 0.65 | 0.53 | 2.11 | 2.22 | 2.11 |
| | Interest Expenses | 1.03 | 1.09 | 0.82 | 4.06 | 6.42 |
| | Other Unallocable Income net of Expenditure | | | | | |
| | Profit Before Tax | 4.31 | 44.04 | 26.27 | 101.49 | 191.90 |
| 3 | Capital Employed | | | | | |
| | Segment Assets (A) | | | | | |
| | Pharma Division | 678.10 | 2,528.41 | 2,158.34 | 678.10 | 2,158.34 |
| | Chemical Division | 1,195.13 | 1,196.39 | 1,165.50 | 1,195.13 | 1,165.50 |
| | Other | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | Total (A) | 1,873.22 | 3,724.80 | 3,323.84 | 1,873.22 | 3,323.84 |
| | Segment Liabilities (B) | | | | | |
| | Pharma Division | 86.53 | 1,564.25 | 1,616.17 | 86.53 | 1,616.17 |
| | Chemical Division | 102.93 | 464.95 | 94.77 | 102.93 | 94.77 |
| | Other | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | Total (B) | 189.46 | 2,029.20 | 1,710.94 | 189.46 | 1,710.94 |
| 4 | Total Capital Employed (Segment Assets-Segment Liabilities) | | | | | |
| | Pharma Division | 591.56 | 964.16 | 542.17 | 591.56 | 542.17 |
| | Chemical Division | 1,092.20 | 731.44 | 1,070.73 | 1,092.20 | 1,070.73 |
| | Other | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| | Total Capital Employed (Segment Assets-Segment Liabilities) | 1,683.77 | 1,695.60 | 1,612.91 | 1,683.77 | 1,612.91 |

Date: 30-05-2022

Place: Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED


RAMESH SHAH
 CHAIRMAN & MANAGING DIRECTOR
 (DIN: 00028819)

**BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED**

CIN NO. L24233MP1985PLC002709

Regd Off: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.) 452015

Email id: bcpcompliance@gmail.com Phone No. 0731-2426718, 2723016-17 Website: www.biofilgroup.net

Audited statement of assets & liabilities as at 31-03-2022

(Amount in Lakhs)

| Sr No. | Particulars | As at 31/03/2022 Audited | As at 31/03/2021 Audited |
|----------|---|--------------------------|--------------------------|
| A | ASSETS | | |
| 1 | Non-current assets: | | |
| | (a) Property, Plant & Equipment | 941.93 | 977.69 |
| | (b) Capital work in Progress | | |
| | (c) Investment Property | | |
| | (d) Goodwill | | |
| | (e) Other Intangible assets | | |
| | (f) Intangible Assets under development | | |
| | (g) Biological Assets other than bearer plants | | |
| | (h) Financial Assets: | | |
| | i. Investments | | |
| | ii. Trade receivables | | |
| | iii. Loans | | |
| | iv. Others (to be specified) | | |
| | (i) Deferred tax assets (net) | | |
| | (j) Other Non- Current Assets | | |
| | Sub-total - Non-current assets | 941.93 | 977.69 |
| 2 | Current assets | | |
| | (a) Inventories | 129.32 | 434.46 |
| | (b) Financial Assets: | | |
| | (i) Investment | | |
| | (ii) Trade receivables | 717.37 | 1,721.79 |
| | (iii) Cash and cash equivalents | 8.50 | 0.97 |
| | (iv) Bank balances other than (iii) above | 6.00 | 43.08 |
| | (v) Loans | | |
| | (vi) Others (to be specified) | | |
| | (c) Current Tax Asset (Net) | | |
| | (d) Other Currents Assets | 70.12 | 145.86 |
| | Sub-total - Current assets | 931.30 | 2,346.16 |
| | TOTAL - ASSETS | 1,873.22 | 3,323.84 |
| B | EQUITY AND LIABILITIES | | |
| 1 | Equity | | |
| | (i) Equity Share Capital | 1,627.38 | 1,627.38 |
| | (ii) Other Equity | 56.39 | (14.47) |
| | Sub-total- Equity | 1,683.77 | 1,612.91 |
| 2 | Liabilities | | |
| | Non-current Liabilities : | | |
| | a. Financial Liabilities | | |
| | (i) Borrowings | | |
| | (ia) Lease Liabilities | | |
| | (ii) Trade Payable | | |
| | (a) total outstanding dues of micro enterprises and small enterprises; and | | |
| | (b) total outstanding dues of creditors other than micro enterprises and small Enterprises. | | |
| | (iii) other Financial Liabilities (other than those specified in item (b), to be specified) | | |
| | b. Provisions | | |
| | c. Deferred tax liabilities (net) | 39.98 | 35.62 |
| | d. Other Non-current Liabilities | | |
| | Sub-total - Non-current liabilities | 1,723.75 | 1,648.53 |
| 3 | Current liabilities | | |
| | a. Financial Liabilities | | |
| | (i) Borrowings | 46.47 | 42.98 |
| | (ia) Lease Liabilities | | |
| | (ii) Trade Payables :- | | |
| | (a) total outstanding dues of micro enterprises and small enterprises; and | | |
| | (b) total outstanding dues of creditors other than micro enterprises and small Enterprises. | 59.63 | 1,585.20 |
| | (iii) other Financial Liabilities [other than those specified in item (C)] | | 14.38 |
| | b. Other Current Liabilities | 16.28 | |
| | c. Provisions | 27.10 | 32.75 |
| | d. Current Tax Liabilities (Net) | | |
| | Sub-total - Current liabilities | 149.48 | 1,675.31 |
| | TOTAL - EQUITY AND LIABILITIES | 1,873.22 | 3,323.84 |

Date: 30-05-2022

Place: INDORE

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)


Statement of cash flows for the year ended 31st March 2022

| | | (Amount in Lakhs) | |
|--------|---|--|--|
| Sr No. | Particulars | For the year ended March 31, 2022 Audited | For the year ended March 31, 2021 Audited |
| A) | Cash flow from operating activities | | |
| | Profit before tax | 101.49 | 191.90 |
| | Adjustments to reconcile profit before tax to net cash used in operating activities | 0.00 | 0.00 |
| | Depreciation of property, plant and equipment | 42.75 | 41.19 |
| | Finance cost | 4.06 | 6.81 |
| | Impact of Gratuity considered in OCI | 1.01 | 0.46 |
| | Net (gain)/ loss on derivative contracts on account of Ind AS adjustments | | |
| | | 149.31 | 240.35 |
| | Provision for doubtful advances/debts | | |
| | Working capital adjustments | 0.00 | 0.00 |
| | Increase/ (Decrease) in Inventory | 305.14 | (265.24) |
| | (Increase)/ Decrease in Trade Receivable, Current | 1004.42 | 1249.07 |
| | (Increase)/ Decrease in Trade Receivable, Non Current | 0.00 | 0.00 |
| | (Increase)/ Decrease in other current assets | 75.74 | (84.32) |
| | (Increase)/ Decrease in other non current assets | 0.00 | 0.00 |
| | (Increase)/ Decrease in other financial assets, current | 0.00 | 0.00 |
| | (Increase)/ Decrease in other financial assets, non-current | 0.00 | 0.00 |
| | Increase/ (Decrease) in trade payables- Current | (1525.57) | (1006.56) |
| | Increase/ (Decrease) in trade payables- Non-Current | 0.00 | 0.00 |
| | Increase/ (Decrease) in other financial liabilities- current | 1.90 | 2.06 |
| | Increase/ (Decrease) in other financial liabilities- Non-current | 0.00 | 0.00 |
| | Increase/ (Decrease) in other liabilities | (1.29) | 43.50 |
| | Cash generated from operations | 9.66 | 178.85 |
| | Tax Expenses | | |
| | Current tax | (27.10) | (32.75) |
| | Deferred tax | (4.02) | (35.45) |
| | Adjustment of tax relating to earlier periods | (0.53) | 0.44 |
| | Net cash flows from operating activities (A) | (21.99) | 111.09 |
| B) | Cash flow from investing activities | | |
| | Payment for purchase and construction of property, plant and equipment | (6.99) | (56.67) |
| | Proceeds from sale of property, plant and equipment | 0.00 | 47.06 |
| | (Increase)/ Decrease in other bank balances | 0.00 | 0.00 |
| | Interest received | 0.00 | 0.00 |
| | Net cash flows from investing activities (B) | (6.99) | (9.61) |
| C) | Cash flow from financing activities | | |
| | Increase/(decrease) in Borrowings | 3.48 | (76.22) |
| | Deemed Investment by Holding Company | 0.00 | 0.00 |
| | Finance cost | (4.06) | (6.81) |
| | Net cash flows from financing activities (C) | (0.58) | (83.03) |
| | Net increase / (decrease) in cash and cash equivalents | (29.55) | 18.45 |
| | Cash and cash equivalents at the beginning of the year | 44.05 | 25.60 |
| | Cash and cash equivalents at the end of the year | 14.49 | 44.05 |
| | Increase / (Decrease) in cash and cash equivalents | (29.55) | 18.45 |

Date: 30/05/2022

Place: INDORE

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED


RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)





Independent Auditor's Report on Standalone Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations")

To,
The Board of Directors
Biofil Chemicals And Pharmaceuticals Limited
Indore (M.P.)

Opinion

We have audited the quarterly standalone financial results of M/s Biofil Chemicals And Pharmaceuticals Limited ("The Company") for the quarter ended March 31, 2022 and the year to date results for the period April 1, 2021 to March 31, 2022, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting Principles generally accepted in India; of the net profit and other comprehensive Income and other financial information for the quarter ended March 31 2022 as well as the year to date results for the period from April 1, 2021 to March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.





Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:





- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.





We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For **MAHESHWARI & GUPTA,**
Chartered Accountants,
F.R.N.: 006179C



CA. SUNIL MAHESHWARI
Partner
M.NO : 403346

PLACE : INDORE

DATE : 30th May, 2022

UDIN : 22403346AJXITI4879